Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106)

N/AActive Not RecruitingNCT07582237

Kang Stem Biotech Co., Ltd.262 enrolled

Overview

Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study

Study Type

OBSERVATIONAL

Enrollment

262

Conditions

Dermatitis, Atopic

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Those who participated in the K0106 clinical trial and received FURESTEM-AD Inj * Those who understand and voluntarily sign an informed consent form Exclusion Criteria: * None

Locations (1)

Bucheon Hospital, Soonchunhyang University

Bucheon-si, South Korea

Outcomes

Primary Outcomes

Safety Assessment

Rate and Number of AESI(Adverse Event of Special Interest) and SS(Special Situation)

Time frame: 5 years follow-up after treatment

Secondary Outcomes

EASI(Eczema Area and Severity Index) Score

Time frame: 1 year, 2 years, 3 years after treatment

IGA(Investigator's Global Assessment) Score

Time frame: 1 year, 2 years, 3 years after treatment

Pruritus NRS(Numerical Rating Scale) Score

Time frame: 1 year, 2 years, 3 years after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.